{"ModuleCode":"PR4205","ModuleTitle":"Bioorganic Principles of Medicinal Chemistry","Department":"Pharmacy","ModuleDescription":"Learning objectives: To learn the different approaches in the design of drugs that are capable of interacting specifically with enzymes, DNA and other cellular targets. Major topics: A mechanistic, chemical and biochemical approach to medicinal chemistry, emphasizing enzymatic and macromolecular targets of drug action. Peptide, peptidomimetics and oligonucleotides. Target students: Pharmacy Final Year and Applied Chemistry (Drug Option)","ModuleCredit":"4","Workload":"2.5-0.5-2-1-4","Prerequisite":"Pass in PR2115 OR PR3101 OR by permission","ExamDate":"2015-11-25T17:00+0800","ExamDuration":"P2H","ExamVenue":"S16-03-07","Types":["Module"],"Lecturers":["Chew Eng Hui","Dymock, Brian William","Matyus, Peter"],"IVLE":[{"Announcements":null,"Forums":[],"Workbins":[],"Webcasts":[],"Gradebooks":[],"Polls":[],"Multimedia":[],"LessonPlan":[],"ID":"adb19b1b-65c6-4c2a-b303-2ec2b2fac607","CourseLevel":"1","CourseCode":"PR4205","CourseName":"BIOORGANIC PRINCIPLES OF MEDICINAL CHEMISTRY","CourseDepartment":"","CourseSemester":"Semester 1","CourseAcadYear":"2015/2016","CourseOpenDate":"/Date(1435507200000+0800)/","CourseOpenDate_js":"2015-06-29T00:00:00","CourseCloseDate":"/Date(1449331140000+0800)/","CourseCloseDate_js":"2015-12-05T23:59:00","CourseMC":"0","isActive":"Y","Permission":"S","Creator":{"UserID":null,"Name":"Esther Woon","Email":null,"Title":null,"UserGuid":"02970446-5214-4d43-9830-0e79941a9171","AccountType":null},"hasGradebookItems":false,"hasTimetableItems":true,"hasGroupsItems":false,"hasClassGroupsForSignUp":false,"hasGuestRosterItems":false,"hasClassRosterItems":false,"hasWeblinkItems":false,"hasLecturerItems":true,"hasDescriptionItems":true,"hasReadingItems":false,"hasAnnouncementItems":false,"hasProjectGroupItems":false,"hasProjectGroupsForSignUp":false,"hasConsultationItems":false,"hasConsultationSlotsForSignUp":false,"hasLessonPlanItems":false,"Badge":0,"BadgeAnnouncement":0,"WebLinks":[],"Lecturers":[{"ID":"efb06abd-86e3-4979-8b47-271756776ee9","User":{"UserID":null,"Name":"Esther Woon","Email":null,"Title":null,"UserGuid":"02970446-5214-4d43-9830-0e79941a9171","AccountType":null},"Role":"Coordinator ","Order":1,"ConsultHrs":null},{"ID":"304bf3bc-1b09-446e-9fef-92ca9f2339fc","User":{"UserID":null,"Name":"Chew Eng Hui","Email":null,"Title":null,"UserGuid":"a14919ca-f556-4df6-8963-73ce8fcb16d3","AccountType":null},"Role":"Co-Lecturer ","Order":2,"ConsultHrs":null},{"ID":"8a399d5b-a33f-43e1-b4f1-a27c679c4f65","User":{"UserID":null,"Name":"Dymock, Brian William","Email":null,"Title":null,"UserGuid":"e1c3c14e-9894-4772-b840-9d028ae93962","AccountType":null},"Role":"Co-Lecturer ","Order":3,"ConsultHrs":null},{"ID":"0f28909c-97dd-4231-852b-6e4128f4a570","User":{"UserID":null,"Name":"Matyus, Peter","Email":null,"Title":null,"UserGuid":"d71da8bc-02b8-4351-a393-73b000a1fef1","AccountType":null},"Role":"Co-Lecturer ","Order":4,"ConsultHrs":null}],"Descriptions":[{"ID":"1e5f053b-8835-4692-be49-41f07234cfff","Title":"Learning Outcomes","Description":"Learning objectives: To learn the different approaches in the design of drugs that are capable of interacting specifically with enzymes, DNA and other cellular targets. Major topics: A mechanistic, chemical and biochemical approach to medicinal chemistry, emphasizing enzymatic and macromolecular targets of drug action. Peptide, peptidomimetics and oligonucleotides. Target students: Pharmacy Final Year and Applied Chemistry (Drug Option)","Order":1},{"ID":"2e5f053b-8835-4692-be49-41f07234cfff","Title":"Prerequisites","Description":"The prerequisite for this module is PR3101 Principles of Medicinal Chemistry.
\nIn addition, this module is designed to integrate topics in cancer biology, pharmacology, biochemistry and medicinal chemistry. Basic background in these topics will help you appreciate the content of the module better. You are advised to do some self-directed reading to enhance your foundation knowledge.
\n
\n","Order":2},{"ID":"3e5f053b-8835-4692-be49-41f07234cfff","Title":"Teaching Modes","Description":"The module will be delivered by lectures and tutorials; and there will be no practical.","Order":3},{"ID":"4e5f053b-8835-4692-be49-41f07234cfff","Title":"Schedule","Description":"
\n\t\t\t\tDate | \n\t\t\t\n\t\t\t\tLecture | \n\t\t\t\n\t\t\t\tStaff | \n\t\t
\n\t\t\t\t11 Aug | \n\t\t\t\n\t\t\t\tL1: Introduction to module and L2: Through hardships to the drug candidate | \n\t\t\t\n\t\t\t\tEW/PM | \n\t\t
\n\t\t\t\t14 Aug | \n\t\t\t\n\t\t\t\tL3: Anti-cancer drugs I. Principle of Chemotherapy. Antimetabolites | \n\t\t\t\n\t\t\t\tPM | \n\t\t
\n\t\t\t\t18 Aug | \n\t\t\t\n\t\t\t\tL4: Anti-cancer drugs II. DNA cross-linking agents. Topoisomerase inhibitors | \n\t\t\t\n\t\t\t\tPM | \n\t\t
\n\t\t\t\t21 Aug | \n\t\t\t\n\t\t\t\tL5: e-Tutorial | \n\t\t\t\n\t\t\t\tPM | \n\t\t
\n\t\t\t\t25 Aug | \n\t\t\t\n\t\t\t\tL6: Hallmarks of Cancer | \n\t\t\t\n\t\t\t\tCEH | \n\t\t
\n\t\t\t\t28 Aug | \n\t\t\t\n\t\t\t\tL7: The Drug Discovery Process | \n\t\t\t\n\t\t\t\tCEH | \n\t\t
\n\t\t\t\t21Sep | \n\t\t\t\n\t\t\t\tL8: Cancer Drug Targets | \n\t\t\t\n\t\t\t\tCEH | \n\t\t
\n\t\t\t\t4 Sep | \n\t\t\t\n\t\t\t\tL9: Bioassays | \n\t\t\t\n\t\t\t\tCEH | \n\t\t
\n\t\t\t\t8 Sep | \n\t\t\t\n\t\t\t\tL12: Tutorial | \n\t\t\t\n\t\t\t\tCEH | \n\t\t
\n\t\t\t\t11 Sep | \n\t\t\t\n\t\t\t\tL24: Monoclonal Antibodies in anticancer therapy | \n\t\t\t\n\t\t\t\tCEH | \n\t\t
\n\t\t\t\t15 Sep | \n\t\t\t\n\t\t\t\tNo Lecture: revision for CA 1 | \n\t\t\t\n\t\t\t\t | \n\t\t
\n\t\t\t\t18 Sep | \n\t\t\t\n\t\t\t\tCA 1 | \n\t\t\t\n\t\t\t\tPM/CEH | \n\t\t
\n\t\t\t\t19 Sep – 27 Sep | \n\t\t\t\n\t\t\t\tRecess Week | \n\t\t\t\n\t\t\t\t | \n\t\t
\n\t\t\t\t29 Sep | \n\t\t\t\n\t\t\t\tL13: Introduction to Epigenetics | \n\t\t\t\n\t\t\t\tEW | \n\t\t
\n\t\t\t\t2 Oct | \n\t\t\t\n\t\t\t\tL14: Epigenetics and You | \n\t\t\t\n\t\t\t\tEW | \n\t\t
\n\t\t\t\t6 Oct | \n\t\t\t\n\t\t\t\tL15: EW-learning | \n\t\t\t\n\t\t\t\tEW | \n\t\t
\n\t\t\t\t9 Oct | \n\t\t\t\n\t\t\t\tL16: Epigenetic Drugs | \n\t\t\t\n\t\t\t\tEW | \n\t\t
\n\t\t\t\t13 Oct | \n\t\t\t\n\t\t\t\tL17: Epigenetic Food | \n\t\t\t\n\t\t\t\tEW | \n\t\t
\n\t\t\t\t16 Oct | \n\t\t\t\n\t\t\t\tL18: Tutorial | \n\t\t\t\n\t\t\t\tEW | \n\t\t
\n\t\t\t\t20 Oct | \n\t\t\t\n\t\t\t\tL10: Overview of Signaling Pathways in Cancer | \n\t\t\t\n\t\t\t\tBWD | \n\t\t
\n\t\t\t\t23 Oct | \n\t\t\t\n\t\t\t\tL11: Inhibitors of Signaling Pathways: The Ras Pathway | \n\t\t\t\n\t\t\t\tBWD | \n\t\t
\n\t\t\t\t27 Oct | \n\t\t\t\n\t\t\t\tL19: Protein Kinase Inhibitors: Imatinib and Gefitinib | \n\t\t\t\n\t\t\t\tBWD | \n\t\t
\n\t\t\t\t30 Oct | \n\t\t\t\n\t\t\t\tL20: Tutorial | \n\t\t\t\n\t\t\t\tBWD | \n\t\t
\n\t\t\t\t3 Nov | \n\t\t\t\n\t\t\t\tL21: Protein Kinase Inhibitors: Sunitinib and Sorafenib | \n\t\t\t\n\t\t\t\tBWD | \n\t\t
\n\t\t\t\t6 Nov | \n\t\t\t\n\t\t\t\tL22: Protein Kinase Inhibitors: Vemurafenib and Ruxolitinib | \n\t\t\t\n\t\t\t\tBWD | \n\t\t
\n\t\t\t\t10 Nov | \n\t\t\t\n\t\t\t\tHappy Deepavali | \n\t\t\t\n\t\t\t\t | \n\t\t
\n\t\t\t\t13 Nov | \n\t\t\t\n\t\t\t\tCA 2 | \n\t\t\t\n\t\t\t\tEW/BWD | \n\t\t
\n\t\t\t\t14 Nov – 20 Nov | \n\t\t\t\n\t\t\t\tReading Week | \n\t\t\t\n\t\t\t\t | \n\t\t
\n\t\t\t\t21 Nov – 5 Dec | \n\t\t\t\n\t\t\t\tExamination Period (Exam date TBC) | \n\t\t\t\n\t\t\t\t | \n\t\t
\n\t\t\t\tTitle | \n\t\t\t\n\t\t\t\tAuthor | \n\t\t\t\n\t\t\t\tEdn/Yr | \n\t\t\t\n\t\t\t\tISBN | \n\t\t\t\n\t\t\t\tPublisher | \n\t\t\t\n\t\t\t\tRemark | \n\t\t
\n\t\t\t\tIntroduction to Medicinal Chemistry, Chapters 12 and 21 | \n\t\t\t\n\t\t\t\tGraham L. Patrick | \n\t\t\t\n\t\t\t\t4th/2009 | \n\t\t\t\n\t\t\t\tISBN-10: 0199234477 \n\t\t\t\tISBN-13: 978-0199234479 | \n\t\t\t\n\t\t\t\tOxford University Press, USA | \n\t\t\t\n\t\t\t\tReference | \n\t\t